Not priti.

The response rates to imatinib among certain populations of patients with GIST. That’s why a novel oral drug avapritinib is now approved specifically for GIST with PDGFRA exon 18 mutations after a phase 1 trial reported a response rate approaching 90%. | FDA 2020